Location: Woburn, MA.
Based on news reporting.
Company, a biotech firm based in Woburn, is set to lay off more than 200 employees following a second rejection from the FDA regarding its skin cancer treatment. The decision comes as the company faces significant challenges in bringing its product to market, which has led to a reevaluation of its workforce needs. The layoffs are a direct response to the setbacks in regulatory approval and are part of a broader strategy to streamline operations. This move underscores the difficulties faced by biotech companies in navigating the complex landscape of drug approval processes.
Woburn biotech cut 200 jobs as of April 17, 2026.
Anonymous by default. Be kind — people reading this may be going through it right now.
No comments yet. Be the first to share your thoughts.
Share your story anonymously — it helps others reading this feel less alone.
Share your story →